ESR1 and breast cancer: A recent meta-analysis[27] revealed that extended endocrine treatment for 10 years could prolong DFS among patients with early breast cancer, especially among ER-positive and postmenopausal patients who received tamoxifen and/or AIs for 5 years followed by AIs for 5 years.